Hormone therapy has been a cornerstone for treating advanced prostate cancer, starving tumors of the male hormones they crave to grow. But it often brings harsh side effects like crushing fatigue, hot flashes, high blood pressure, and loss of muscle mass that make daily life a struggle for many men. Now, a major new UK […]
The HITMAN-PC trial represents a targeted metabolic approach to managing biochemical relapse in prostate cancer, combining hydroxychloroquine (HCQ) and SUBA-itraconazole (SI) to disrupt lysosomal function and cholesterol trafficking in hormone-sensitive disease. In this phase 1 dose-escalation study, 11 men (median age 73, baseline PSA 4.4 ng/mL, PSA doubling time 5.3 months) received fixed SI at […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Another week full of interesting and promising clinical trials! The approaches are multiplying, and immunotherapies are advancing even for prostate cancer, which is beginning to respond. Stay strong and fight on! As usual, we also have a podcast if […]
P‑PSMA‑101 is an experimental CAR‑T cell therapy being tested in men with metastatic castration‑resistant prostate cancer (mCRPC) who have already received multiple standard treatments (up to 10 before enrollment). In the phase 1 trial, 33 men with heavily pretreated mCRPC received P‑PSMA‑101, an autologous PSMA‑targeted CAR‑T product enriched in stem‑cell‑like memory T cells and engineered […]
A remarkable case published in Annals of Internal Medicine: Clinical Cases highlights a man with metastatic, castration‑resistant prostate cancer who achieved a complete and durable response to pembrolizumab after exhausting multiple standard therapies. The patient had previously received abiraterone‑based treatment followed by chemotherapy, and then olaparib, all of which he had progressed on, leaving him […]
The PARTHENON trial tests AZD4956, an experimental oral drug that blocks SMARCA2, a protein helping cancer cells rearrange their DNA to keep growing. In tumors already “weak” at fixing DNA damage due to homologous recombination deficiency (HRD), shutting down SMARCA2 creates a double hit: cells can’t remodel chromatin or repair errors, leading to collapse. This […]
SYS6043 is a new type of antibody-drug conjugate, or ADC. It zeroes in on B7-H3, a protein that is expresse by advanced tumors but almost not at all on healthy cells. The antibody part sticks to B7-H3, gets pulled inside the cancer cell, and releases a topoisomerase I inhibitor that breaks the cell’s DNA and […]
The AM006 clinical trial, tests HER2 FPBMC anti-CD3 x anti-HER2 bispecific antibody (HER2Bi)-armed activated T cells, in patients with HER2-positive metastatic prostate and breast cancer. For prostate cancer patients, this targets the 20-30% of metastatic cases overexpressing HER2, offering a fresh immune-based option after standard therapies fail. HER2 FPBMC starts with a simple blood draw […]
The phase 3 trial CAPItello-281, has delivered compelling evidence that capivasertib combined with abiraterone could transform treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC), a subtype affecting a substantial portion of advanced cases. In this double-blind study, 1012 patients with PTEN deficiency (defined rigorously as 90% or more viable malignant cells showing no cytoplasmic staining […]
Radium-223 plus enzalutamide significantly boosts survival for men with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases, according to final results from the Phase 3 PEACE-3 trial presented at ASCO GU 2026. In this study of 446 patients with at least two bone metastases who were asymptomatic or only mildly symptomatic, adding six infusions of […]